How large is the global CT scanner market?

The global CT scanner systems market is estimated at US$7.2 billion in 2024A and is forecast to reach US$11.0 billion by 2035E, representing a 3.9% CAGR. The broader core CT ecosystem—including service contracts, replacement tubes and parts, software upgrades, vendor-net CT AI, and enterprise orchestration—is forecast to expand from US$14.8 billion to US$25.4 billion over the same period.

What is included in the global CT market forecast?

The report covers new CT systems, service and aftermarket revenue, replacement X-ray tubes and parts, software upgrades, vendor-net clinical AI, and CT-attributable enterprise AI orchestration. It also analyzes selected adjacencies, including CT-attributable contrast media and mobile CT services. Hospital labor, facility fees, professional fees, provider reimbursement, PET/CT radiopharmaceuticals, veterinary CT, and industrial CT are excluded from the core market.

What is driving growth in the CT scanner market through 2035?

Growth is being driven by a combination of replacement demand, installed-base expansion in lower-density markets, premium scanner mix, spectral and photon-counting CT adoption, service and lifecycle revenue, software upgrades, cardiac CT growth, and clinical AI monetization. In mature markets, value growth depends more on premium replacement, uptime, software, and AI than on rapid unit expansion.

How important is photon-counting CT to the market outlook?

Photon-counting CT is the fastest-growing premium CT segment, but it is not expected to replace the global installed base rapidly. Its near- and medium-term impact is primarily a premium value-mix shift concentrated in academic centers, flagship hospitals, cardiovascular programs, oncology centers, and advanced tertiary-care institutions. Spectral and dual-energy CT remain important because they provide a more accessible premium pathway for many buyers.

How large is the CT AI market, and which applications will drive growth?

Vendor-net CT AI revenue, including CT-attributable orchestration, is forecast to increase from approximately US$0.7 billion in 2024A to US$3.5 billion in 2035E. The largest modeled categories are CCTA and cardiac CT AI, followed by enterprise AI orchestration. Stroke, lung screening, oncology, incidental-finding, workflow, and reporting applications also contribute, but each has a different reimbursement, adoption, and commercial pathway.

Which regions and countries are covered in the report?

The report provides global and regional analysis across North America, Europe, China, Japan, broader Asia-Pacific, Latin America, and the Middle East and Africa. Detailed country coverage includes the United States, Canada, Germany, the United Kingdom, France, Italy, Spain, China, Japan, India, Brazil, Mexico, Saudi Arabia and the UAE, and South Africa.

What does the Global Mammography Horizon report cover?

The report covers the global mammography market and broader breast imaging ecosystem from 2024A to 2035F. It includes dedicated mammography systems, FFDM, digital breast tomosynthesis, contrast-enhanced mammography, mammography AI/workflow, service and aftermarket, mobile mammography, interventional breast pathways, breast ultrasound, and breast MRI adjacencies.

Which companies are discussed in the report?

The report discusses systems OEMs, AI vendors, workflow platforms, interventional breast pathway companies, provider networks, mobile access models, China/value-tier challengers, detector suppliers, and CEM/photon-counting enabling-stack companies. Examples include Hologic, GE HealthCare, Siemens Healthineers, Fujifilm, Canon Medical, United Imaging, Wandong, ScreenPoint, Lunit/Volpara, RadNet/DeepHealth/iCAD, Visage/Pro Medicus, Sectra, Mammotome, BD, Merit Medical, Varex, Bayer, Bracco, and Guerbet.

What is the Core Mammography Market?

The Core Mammography Market includes dedicated mammography systems, mammography-specific service contracts, mammography-specific software and workstations, and mammography AI/workflow revenue. It does not blend in breast biopsy, breast ultrasound, or breast MRI without explicit bridge labeling.

How does the report treat AI revenue?

The report separates vendor-net AI/workflow revenue from provider-gross AI economics. Vendor-net revenue refers to software revenue booked by vendors, OEMs, or workflow platforms. Provider-gross economics include productivity, patient-pay, reimbursement, recall management, and downstream workflow value captured by providers.

How is this report different from a standard mammography equipment market report?

A standard equipment report often focuses on unit shipments, installed base, ASPs, and system revenue. This Horizon report adds market-structure analysis, AI monetization, CEM strategy, interventional breast pathway economics, breast US/MRI adjacencies, regional archetypes, competitive control planes, and strategic frameworks for commercial decision-making.

Who should buy this report?

This report is designed for medical imaging OEMs, breast health strategy teams, AI and workflow vendors, enterprise imaging platforms, biopsy and interventional breast companies, detector and contrast suppliers, provider networks, investors, private equity, distributors, and public-sector screening or procurement stakeholders.

Strategic Frameworks & Market Signals

Go beyond the headlines with Strategic Frameworks & Market Signals – decoding critical industry shifts into actionable intelligence. We provide the models and deep competitive analysis leaders need to anticipate market moves, not just react to them.

Strategic Frameworks & Market Signals

Strategic Frameworks & Market Signals

The Shift to Capacity Control

Reporting AI: The New Control Layer for Medical Imaging

Imaging AI Market Signal – The Shift to Platform Control

Sectra Completes Oxipit Acquisition (2026-04-15)

Neuropacs De Novo: First FDA-Authorized AI Pathway for Chronic Neurodegenerative Disease Differentiation

The Highest-Value AI Frontier Is Shifting from Interpretation to Acquisition

RadNet Acquires Gleamer: The Radiology AI Platform Consolidation Thesis Takes Shape

GE HealthCare: Procedure-Room AI Platformization Accelerates

ScreenPoint Medical: MASAI makes breast AI procurement-grade screening infrastructure

Siemens Healthineers: MRI’s next battleground is “constraint removal,” not “image quality.”

MRI acquisition automation moves from “pilot” to provider-backed platform

Aidoc: FDA “multi-triage” clearance marks the platform bundling phase

The Battle for the Cath Lab Cockpit: Why Philips’ Acquisition of SpectraWAVE Resets the Interventional Stack

Quick Links

Solutions

Contact us